suloctidil | 54767-75-8

• 物质功能分类: 分析化学 - 标准品 - 法医和兽医标准品
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: suloctidil
• 英文别名: (1S,2R)-2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol；(1S,2R)-2-(octylamino)-1-(4-propan-2-ylsulfanylphenyl)propan-1-ol
• CAS: 54767-75-8
• 化学式: C₂₀H₃₅NOS
• 分子量: 337.57
• InChiKey: BFCDFTHTSVTWOG-YLJYHZDGSA-N

物化性质

• 熔点：
  62.5°C
• 沸点：
  467.3±35.0 °C(Predicted)
• 密度：
  0.9880 (rough estimate)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  23
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  57.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S36
• 危险类别码：
  R22
• WGK Germany：
  3
• RTECS号：
  DO8910000

制备方法与用途

概述

舒洛地尔是一种钙通道阻滞剂，具有抗血管痉挛和抗血栓形成的作用。研究发现，它在体外能够抑制白假丝酵母菌的生长；另有研究表明，舒洛地尔联合氟康唑使用时，对新型隐球菌有抑制作用。

用途

舒洛地尔的中文别名是索罗克替。作为一种强效的抗血小板药物，临床上主要用于治疗血栓。

文献信息

• Methods for Screening Interleukin-6 (IL-6) Signal Transduction Inhibitors
  申请人：Kitamura Toshio

  公开号：US20090280483A1

  公开（公告）日：2009-11-12

  The present invention provides methods for screening compounds which inhibit activation of a member of the IL-6 signaling pathways, comprising: (a) a positive screening step using a cell capable of being killed by IL-6 stimulation to select compounds which inhibit death of the cell when it is stimulated by IL-6; and then (b) a biochemical screening step to further select compounds which inhibit activation of a member of the IL-6 signaling pathways by a biochemical means from the compounds selected in step (a). The present invention also provides compounds which inhibit activation of a member of the IL-6 signaling pathways identified using said methods.
• SSAT mRNA TRANSLATION REPRESSION AND ACTIVATION
  申请人：Merali Salim

  公开号：US20140234827A1

  公开（公告）日：2014-08-21

  The invention provides an isolated nucleic acid having a sequence encoding a spermidine/spermine acetyltransferase (“SSAT”), wherein translation of an mRNA comprising the encoded SSAT has increased basal translation and increased stimulated translation, compared to a wild-type mRNA encoding SSAT. Methods of use for the nucleic acid are also provided. Methods and compositions are also provided for reducing ischemia-reperfusion injury in organs or tissue for transplantation.
• COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF PROTEINOPATHIES
  申请人：Washington University

  公开号：US20210228591A1

  公开（公告）日：2021-07-29

  The present disclosure relates generally compositions and methods of using the same for the treatment of proteinopathies (e.g. Alpha-1-antitrypsin deficiency, Non-alcoholic fatty liver disease, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Huntington's disease) with one or more proteotoxicity reducing agents.
• US9585380B2
  申请人：——

  公开号：US9585380B2

  公开（公告）日：2017-03-07
• [EN] COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF PROTEINOPATHIES<br/>[FR] COMPOSITIONS ET PROCÉDÉS D'UTILISATION DE CELLES-CI POUR LE TRAITEMENT DE PROTÉINOPATHIES
  申请人：UNIV WASHINGTON

  公开号：WO2019204764A1

  公开（公告）日：2019-10-24

  The present disclosure relates generally compositions and methods of using the same for the treatment of proteinopathies (e.g. Alpha-1-antitrypsin deficiency, Non-alcoholic fatty liver disease, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Huntington's disease) with one or more proteotoxicity reducing agents.